Your browser doesn't support javascript.
loading
Trajectory of anxiety/depressive symptoms and sleep quality in individuals who had been hospitalized by COVID-19: The LONG-COVID-EXP multicenter study.
Fernández-de-Las-Peñas, César; Arias-Navalón, José A; Martín-Guerrero, José D; Pellicer-Valero, Oscar J; Cigarán-Méndez, Margarita.
Afiliación
  • Fernández-de-Las-Peñas C; Department of Physical Therapy, Occupational Therapy, Physical Medicine and Rehabilitation, Universidad Rey Juan Carlos (URJC), Madrid. Spain. Electronic address: cesar.fernandez@urjc.es.
  • Arias-Navalón JA; School of Medicine, Universidad CEU-San Pablo, Madrid, Spain.
  • Martín-Guerrero JD; Intelligent Data Analysis Laboratory, Department of Electronic Engineering, ETSE (Engineering School), Universitat de València (UV), Burjassot, Valencia, Spain; Valencian Graduate School and Research Network of Artificial Intelligence (ValgrAI), València, Spain.
  • Pellicer-Valero OJ; Image Processing Laboratory (IPL), Universitat de València, Parc Científic, Paterna, València, Spain.
  • Cigarán-Méndez M; Department of Psychology, Universidad Rey Juan Carlos (URJC), Madrid, Spain.
J Psychosom Res ; 179: 111635, 2024 Apr.
Article en En | MEDLINE | ID: mdl-38432061
ABSTRACT

OBJECTIVE:

To apply Sankey plots and exponential bar plots for visualizing the evolution of anxiety/depressive symptoms and poor sleep in previously hospitalized COVID-19 survivors.

METHODS:

A sample of 1266 subjects who were hospitalized due to a SARS-CoV-2 from March-May 2020 were assessed at 8.4 (T1), 13.2 (T2) and 18.3 (T3) months after hospitalization. The Hospital Anxiety and Depression Scale was used to determine anxiety (HADS-A) and depressive (HADS-D) symptoms. The Pittsburgh Sleep Quality Index (PSQI) evaluated sleep quality. Clinical features, onset symptoms and hospital data were collected from medical records.

RESULTS:

Sankey plots revealed that the prevalence of anxiety symptomatology (HADS-A ≥ 8 points) was 22.5% (n = 285) at T1, 17.6% (n = 223) at T2, and 7.9% (n = 100) at T3, whereas the prevalence of depressive symptoms (HADS-D ≥ 8 points) was 14.6% (n = 185) at T1, 10.9% (n = 138) at T2, and 6.1% (n = 78) at T3. Finally, the prevalence of poor sleep (PSQI≥8 points) decreased from 32.8% (n = 415) at T1, to 28.8% (n = 365) at T2, and to 24.8% (n = 314) at T3. The recovery curves show a decrease trend visualizing that these symptoms recovered the following years after discharge. The regression models did not reveal medical records associated with anxiety/depressive symptoms or poor sleep.

CONCLUSION:

The use of Sankey plots shows a fluctuating evolution of anxiety/depressive symptoms and poor sleep during the first years after the infection. In addition, exponential bar plots revealed a decrease prevalence of these symptoms during the first years after hospital discharge. No risk factors were identified in this cohort.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: COVID-19 / Trastornos del Inicio y del Mantenimiento del Sueño Límite: Humans Idioma: En Revista: J Psychosom Res Año: 2024 Tipo del documento: Article

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: COVID-19 / Trastornos del Inicio y del Mantenimiento del Sueño Límite: Humans Idioma: En Revista: J Psychosom Res Año: 2024 Tipo del documento: Article